BMY
Bristol Myers Squibb
$55.53
▲ 1.5%Updated Today 5:06 AM ET
▲ Up 15.3% over the last 12 months
Market Cap
$113.40B
P/E
19.01x
Forward P/E (est.)
15.05x
ROE
41.6%
Revenue Growth
1.8%
EPS Growth
26.3%
Profit Margin
12.3%
FCF Yield
15.4%
Debt / Equity
2.44x
ROIC
—
Interest Coverage
—
Current Ratio
1.42x
Dividend Yield
4.5%
Implied Growth (rev. DCF)
-2.1%
Rating Score
60/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BMY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BMY trades near $55.53, around its 50-day average ($57.21) and 200-day average ($53.67). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 54 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. BMY's is $1.32 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BMY found buyers near $53.44 (support) and sellers near $59.78 (resistance); its 52-week range is $42.52–$62.89. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Bristol Myers Squibb (BMY) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $113.40B.
In its latest reported year it generated about $48.19B in revenue and $7.05B in net profit.
Our model rates BMY Favorable (60/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
1.0%
Revenue moved from $46.38B in 2021 to $48.19B in 2025, a 1.0% compound annual growth rate. The most recent year was roughly flat (1.8%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
53.7%
Operating Margin
17.1%
Net Margin
14.6%
ROE
41.6%
Bristol Myers Squibb keeps about 12.3% of each sales dollar as net profit, with a 53.7% gross margin and 17.1% operating margin. Return on equity is 41.6%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$44.14B
Net Debt
$34.57B
Net Debt / EBITDA
—
Debt / Equity
2.44x
Leverage: debt-to-equity is 2.4x, with a current ratio of 1.4x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $44.14B of total debt against $9.57B of cash.
Operating CF
$14.16B
Free Cash Flow
$12.85B
FCF Margin
26.7%
In the latest year Bristol Myers Squibb produced about $14.16B of operating cash flow and $12.85B of free cash flow after capital spending. That is a free-cash-flow yield of about 15.4% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
19.01x
P/S
2.37x
P/B
5.9x
EV / EBITDA
—
BMY trades at 19.0x trailing earnings (about 15.1x on estimated forward earnings), 2.4x sales, and 5.9x book value. Reverse-engineering today's price implies the market expects roughly -2.1% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How BMY stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), BMY ranks #18 of 59 by our overall rating. It trades at a discount versus the sector on earnings (19x P/E vs. 25.5x median) with a higher return on equity (41.6% vs. 14.9%) and slower revenue growth (1.8% vs. 7.9%).
P/E vs sector
19x
median 25.5x
ROE vs sector
41.6%
median 14.9%
Growth vs sector
1.8%
median 7.9%
Sector rank
#18
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$45.14 – $77.97
vs. $55.53 today · expected CAGR -4% – 7%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $49.64B | $51.13B | $52.66B | $54.24B | $55.87B |
| Net income | $7.45B | $7.67B | $7.90B | $8.14B | $8.38B |
| EPS | $3.65 | $3.76 | $3.87 | $3.98 | $4.10 |
| Share price (low) | $40.11 | $41.31 | $42.55 | $43.83 | $45.14 |
| Share price (high) | $69.28 | $71.36 | $73.50 | $75.70 | $77.97 |
| CAGR (low–high) | -28% / 25% | -14% / 13% | -8% / 10% | -6% / 8% | -4% / 7% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BMY:
- Strong return on equity (41.6%) shows capital is put to work well.
- Healthy free-cash-flow yield (~15.4%) funds buybacks and dividends.
- Pays a 4.5% dividend on top of any price gains.
- Our model's overall read is Favorable (60/100).
The case against BMY:
- Revenue growth is slow (1.8%), limiting the upside engine.
- Elevated leverage (debt/equity 2.4x) adds financial risk.
Balance-sheet risk — debt/equity of 2.4x magnifies the impact of higher rates or weaker earnings.
Growth risk — sluggish revenue (1.8%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Bristol Myers Squibb is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 19.0x earnings, which our model scores Favorable (60/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
BMY — frequently asked questions
Is BMY a good stock to buy?
We don't give buy or sell advice. Our model rates Bristol Myers Squibb Favorable (60/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is BMY's rating on The Stocks School?
Bristol Myers Squibb currently scores 60/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does BMY's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Bristol Myers Squibb's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for BMY calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this BMY analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell BMY. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.